Epigenome-Based Precision Medicine in Lung Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Lung cancer remains a leading cause of cancer mortality globally, with poor survival rates attributed to early metastasis and recurrence.
• Current treatments, including precision medicines targeting oncogenic mutations, face challenges like lack of targetable mutations and acquired drug resistance.
• Tumor heterogeneity and high mutational density further complicate effective lung cancer treatment.

Purpose of the Study:

• To review the potential of epigenetic therapy as an alternative strategy for lung cancer treatment.
• To highlight the innovative approach of epigenetic priming in conjunction with conventional or targeted therapies.
• To address the limitations of current lung cancer treatments, including drug resistance and tumor heterogeneity.

Main Methods:

• Review of current literature on lung cancer treatment modalities.
• Exploration of epigenetic mechanisms and their therapeutic potential.
• Analysis of epigenetic priming as a strategy to enhance standard and targeted cancer therapies.

Main Results:

• Epigenetic therapy shows promise in overcoming tumor heterogeneity and drug resistance.
• Epigenetic priming can potentially sensitize cancer cells to subsequent treatments.
• This approach may offer a viable alternative for patients lacking targetable mutations or developing resistance.

Conclusions:

• Epigenetic priming represents a promising innovative strategy in precision medicine for lung cancer.
• Combining epigenetic priming with existing therapies may improve treatment efficacy and patient outcomes.
• Further research into epigenetic modifications could lead to novel therapeutic avenues for lung cancer.